• Explore /
  • Poster
  • / Validation of the association of RECIST 1.0 changes with survival in men with metastatic castration resistant prostate cancer (mCRPC) treated on SWOG Study S0421.

Validation of the association of RECIST 1.0 changes with survival in men with metastatic castration resistant prostate cancer (mCRPC) treated on SWOG Study S0421.

Abstract Poster

Authors

null

Gregory Russell Pond

Ontario Clinical Oncology Group, Hamilton, ON, Canada

Gregory Russell Pond , Guru Sonpavde , Melissa Plets , Catherine M. Tangen , Maha Hussain , Primo Lara Jr., Amir Goldkorn , Mark Garzotto , Philip C. Mack , Celestia S. Higano , Nicholas J. Vogelzang , Ian Murchie Thompson Jr., Przemyslaw Twardowski , Peter J. Van Veldhuizen , Neeraj Agarwal , Michael Anthony Carducci , Paul Monk III, David I. Quinn

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary (Prostate) Cancer

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Prostate Cancer - Advanced Disease

Citation

J Clin Oncol 34, 2016 (suppl; abstr 5079)

DOI

10.1200/JCO.2016.34.15_suppl.5079

Abstract #

5079

Poster Bd #

430

Abstract Disclosures

Similar Posters

First Author: Gregory Russell Pond

First Author: Stephane Oudard

First Author: Daniel Peter Petrylak

First Author: Ankit Madan